L DESIGN — 2293988
Application number
2293988
Registration number
TMA1367388
Type(s)
Design
Category
Trademark
CIPO Status
REGISTERED
TM5 status
LIVE/REGISTRATION/Issued
and Active
The trademark application has been registered with the Office.
Filed
2023-11-21
Registered
2025-12-12
Registration Expiry Date
2035-12-12
Registered Owner
ELI LILLY AND COMPANY
LILLY CORPORATE CENTER
INDIANAPOLIS, IN 46285
UNITED STATES OF AMERICA
Agent
BORDEN LADNER GERVAIS LLP
World Exchange Plaza
100 Queen Street, Suite 1300
Ottawa
ONTARIO K1P1J9
Documents
Index headings
- L
Vienna information (Code & Description)
- 26.11.1
- One line or one band
- A 26.11.12
- Curved lines or bands (except a 26.11.13)
- 27.5.1
- Letters presenting a special form of writing
- A 27.5.8
- Letters linked to or containing a figurative element -- Note: Letters representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object are classified in division 27.3.
- A 27.5.21
- One letter
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations for the treatment of bursitis, tendonitis and osteonecrosis; pharmaceutical preparations for the treatment of depression, bipolar depression, and cognitive impairment associated with schizophrenia; pharmaceutical preparations for the treatment of cluster headaches and migraines; pharmaceutical preparations for the treatment of rheumatoid arthritis, psoriatic arthritis, lupus and spondyloarthropathy; pharmaceutical preparations for the treatment of muscle diseases and disorders namely myopathies, chronic fatigue syndrome and fibromyalgia; diagnostic reagents for medical diagnostic use; pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; pharmaceutical preparations for the diagnosis of oncological diseases and disorders; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment and the prevention of dementia; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dermatitis, eczema and psoriasis; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, ulcerative colitis; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders namely irritable bowel disorders and symptoms; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of mental health disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for treating cardiovascular diseases; pharmaceutical preparations for treating hypoglycemia; pharmaceutical preparations for treatment of autoimmune diseases and disorders; radiopharmaceutical preparations for diagnostic purposes;
Services (Nice class & Statement)
- 44
- (1) Providing health and medical information in the field of oncology; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing information relating to the preparation and dispensing of medications; providing information to patients in the field of administering medications; providing medical information in the field of autoimmune diseases and disorders; providing medical information in the field of cancer treatment; providing medical information in the field of endocrinology; providing medical information in the field of gastroenterology; providing medical information in the field of inflammatory bowel disease; providing medical information in the field of pharmaceutical preparations for the treatment of headaches; providing medical information in the treatment and prevention of endocrine diseases and disorders; providing medical information in the treatment and prevention of metabolic diseases and disorders;
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2023-11-21 | ||
| Created | 2023-11-21 | ||
| Formalized | 2023-11-21 | ||
| Pre-Assessment Letter Sent | 2023-12-07 | Retired Goods or Services | |
| Search Recorded | 2025-07-09 | ||
| Approved | 2025-07-17 | APPROVED BY PROGRAM EX200M1 | |
| Approval Notice Sent | 2025-07-17 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2025-09-24 | Vol.72 Issue 3700 | |
| Registration Pending | 2025-12-12 | ||
| Registered | 2025-12-12 | 2035-12-12 |